City of Hope’s Post

Better Tools for Better Estimates: How can we improve cancer data by finding better ways to handle missing data? Since cancer registries often face(d) the problem of missing data, we wanted to know how we can deal with this problem in an analytical way. See our new publication with Cornelia Richter, Lea Wildisen, PhD, and Sarah R. Haile. #cancerregistration #cancer University of Zurich, Epidemiology, Biostatistics and Prevention Institute and Nationale Krebsregistrierungsstelle (NKRS) https://lnkd.in/eAFRh7py

Colorectal cancer, also known as colon cancer or bowel cancer, will soon be the leading cause of death from cancer in the under 50s. The increasing number of colorectal cancer cases in young adults worldwide is alarming, but there's positive news. In today's podcast, Dr Andy Chan shares encouraging information: colorectal cancer may be preventable, and there are practical steps you can take now to reduce your risk. Dr Chan is a professor of medicine at Harvard Medical School and chief of the clinical and translational epidemiology unit at Massachusetts General Hospital. He is fascinated by the gut microbiome and has been working closely with ZOE since the very early days. He is a lead researcher in the brand new Cancer Grand Challenges Team PROSPECT, working to better understand what leads to colorectal cancer, alongside ZOE's chief scientist, Dr Sarah Berry, and my scientific co-founder, Tim Spector. In this episode, we discuss how your diet can impact your cancer risk, the potential link between changes in your gut microbiome and colorectal cancer development, and preventive measures you can take today. To learn more, click the link in the comments to listen to the full episode.

#cancerresearch #epidemiology #oncology #health https://lnkd.in/gRDX5crG Epidemiologic cohorts of cancer etiology have contributed substantially to the current understanding of #cancer #risk #factors. Advancements in technologies could facilitate more precise, efficient and scalable assessments of emerging risk factors, ranging from ‘cells to society’. Because of the increasingly recognized necessity of addressing the roles of structural and social determinants of health, as well as the inclusion of underserved and understudied populations, a new generation of epidemiologic cohorts for cancer is warranted. Epidemiologic cohorts of cancer etiology involve following individuals over time to track the incidence of new cancers and other cancer-related outcomes. It is one of the most methodologically robust study designs for inferring causal associations between exposures and cancer. Because exposure is ascertained prior to cancer diagnosis, it is thus presumably unbiased by cancer occurrence or memory recall and therefore is an optimal approach for identifying cancer aetiological risk factors.

This powerful new analysis just published in Cancer highlights that the burden of cancer is on track to double in the coming decades, killing 10 million men each year by 2050. Prostate cancer will overtake lung cancer as the most deadly cancer in men if we don’t find better ways to diagnose and treat it.   This underscores the value of our work at Lucida Medical Ltd to change this trajectory with better ways to screen, diagnose and treat cancers. Many congratulations to Dr. Habtamu Mellie Bizuayehu (PhD, Epidemiology) and co-authors for this research. Extract from Fig.2 – Leading cancers by mortality, forecast for 2050, all age groups in males. Full paper (open access): https://lnkd.in/e9bZwQur CC license: https://lnkd.in/e6qui62

Don't miss our live poster presentation tomorrow at 2024 ASCO® Annual Meeting and be sure to read our three online abstract publications as well. Details below: 📌 Assessing secular trends in lung cancer stage in the United States community oncology setting from 2013 to 2023 👩🔬 Jess Paulus, ScD Epidemiology 🕘 9 a.m. - 12 p.m. CT 📍 Poster Board #373 📌 Real-world clinical effectiveness and treatment patterns in the early-stage esophageal/gastroesophageal junction cancer (EC/GEJC) population treated in the community oncology setting in the United States 🔗 https://lnkd.in/gsykMtac 📌 Real-world (rw) treatment (tx) patterns and clinical outcomes in patients (pts) with locally advanced/metastatic urothelial carcinoma (la/mUC): Insights from The US Oncology Network electronic health record (EHR) 🔗 https://lnkd.in/grAiJBmP 📌 Pan-tumor circulating tumor DNA testing in the community oncology setting. 🔗 https://lnkd.in/gT_fmB82

#Environmental #behavioral & #genetic variables all have a role in the development of #obesity. #Sedentarylifestyles and #poordiets marked by large intakes of #calories #carbohydrates and unhealthy #fats are key culprits. #MyHealth #earlyDetectionSaveLives #endcancer

📣 BLACK FAMILY CANCER AWARENESS WEEK: Did you know that Black and African American people have higher death rates than all other racial/ethnic groups for many, although not all, cancer types? NCI-funded researchers are working to identify ways to improve outcomes for groups disproportionately affected by cancer. Their research efforts range from designing and implementing culturally appropriate health interventions, to improving access to care and connecting underrepresented populations to clinical trials, to examining biological and genetic factors that may explain differences in rates of fast-growing cancers. Researchers with NCI Cancer Epidemiology and Genetics have developed risk assessment tools for breast, colon, lung, thyroid and skin cancers that take specified racial/ethnic groups and age intervals into account. These tools are freely available to other researchers. ➡ Learn more: https://lnkd.in/e67k_bay National Cancer Institute (NCI), FDA, The National Institutes of Health, National Institutes of Health (NIH): Intramural Research Program (IRP) #CancerResearch #BlackFamCan #HealthEquity #Innovation

A total of 40,797 cancer cases were reported, with 23,021 (56%) being female and 17,776 (44%) being male (Fig. 1A). The most common cancer among all patients are breast cancer, accounting for 24.1% of cases, followed by oral cavity cancer (9.6%), colorectal cancer (4.9%), esophageal cancer (4.2%), liver cancer (3.9%), ovarian cancer (3.8%), central nervous system cancer (3.8%), non-Hodgkin lymphoma (3.6%), lung cancer (3.5%), and prostate cancer (2.7%) Exploring the Burden of Cancer in Pakistan: An Analysis of 2019 Data Published: 25 April 2023 Journal of Epidemiology

#Melanoma #DecisionDx-Melanoma #cancerstaging #Riskstratification --"Relying on staging alone to determine a melanoma patient’s prognosis misses patients with aggressive tumor biology who may be at higher risk of recurrence, metastasis or death from their disease” ---Study Finds DecisionDx®-Melanoma Significantly Improves the Risk Stratification of Patients with Stage I Melanoma Compared to American Joint Committee on Cancer 8th Edition Staging ---Study results, which include 5,651 patients in the National Cancer Institute’s Surveillance, Epidemiology and End Results (SEER) Program Registries, support the use of DecisionDx-Melanoma in stage I melanoma to help inform clinical decision-making https://lnkd.in/gt3NsAeU

📊 Understanding US Cancer Trends 2024 🔍 Insights: The American Cancer Society's 2024 report projects 2,001,140 new cancer cases and 611,720 deaths in the U.S. 👏 Progress: Mortality rates have dropped since 1991, saving 4 million lives due to reduced smoking, early detection, and improved treatments. 🚨 Challenges: Six of the top 10 cancers, including breast, pancreas, and uterine corpus, show rising incidence rates. Young adults face increased rates in cervical and colorectal cancers. ⚖️ Disparities: Persistent gaps in mortality rates exist among ethnic groups, emphasizing the need for targeted interventions, especially for American Indian, Alaska Native, and Black individuals. The full article has open acess. #CancerTrends #PublicHealth #HealthEquity #CancerPrevention